Medicine
Zaltrap 200 mg/8 mL injection
Zaltrap 200 mg/8 mL injection is a prescription medicine containing Aflibercept for intravenous use, marketed by Sanofi-Aventis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store ZALTRAP vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Keep the…
Key facts
- Active ingredient (INN)
- Aflibercept
- Brand
- Zaltrap
- Strength
- 200 mg/8 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 8 mL
- Marketing authorisation holder
- Sanofi-Aventis
- Manufacturer
- Sanofi-Aventis
- Origin register
- US FDA, United States
- Storage
- Store ZALTRAP vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Keep the vials in the original outer carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX44 Aflibercept
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 August 2012
- Identifiers
- RxCUI 1723187, 1723189, 1723193 +1DailyMed set ID f6725df6-50ee-4b0a-b900-d02ba634395dNDC 0024-5841Application BLA125418
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 8 mL in 1 vial | 0024-5841-01 | sanofi-aventis | 3 August 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Aflibercept
Clinical summary
Aflibercept is a vascular endothelial growth factor inhibitor indicated for the treatment of eYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with, among other approved uses. MedsAcross supplies Aflibercept for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AfliberceptFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EYLEA prescribing information (Regeneron Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Eylea: European public assessment report (EPAR) · European Medicines Agency
- Zaltrap: European public assessment report (EPAR) · European Medicines Agency
Need Zaltrap 200 mg/8 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.